


# *Plasmodium vivax* MALARIA mRNA VACCINE R&D CONSORTIUM




JETSUMON SATTABONGKOT PRACHUMSRI, PHD.

MAHIDOL VIVAX RESEARCH UNIT (MVRU)  
CENTER OF EXCELLENCE FOR MALARIA, FACULTY OF TROPICAL MEDICINE  
MAHIDOL UNIVERSITY, BANGKOK, THAILAND

# Update on *P. vivax* mRNA vaccines



- Pvs25
  - 2-dose immunization: 100% transmission-blocking for >6 months
  - Induced memory B cell and T cell responses
  - Ready for non-human primate testing with clinically approved formulation (Chula VRC)
- PvCSP & Pvs230
  - Construct optimization in progress using mRNA vaccine technology




Chulalongkorn University, Thailand

- Chula Vaccine Research Center (Chula VRC,)
- National Primate Research Center of Thailand,

*Indicative collaboration  
plan to develop mRNA  
vaccine for Malaria P.  
vivax*



# Consortium plan to develop mRNA vaccine for Malaria *P. vivax*



# CURRENT INSTITUTES JOINING *P. vivax* CONSORTIUM



Mahidol University  
*Wisdom of the Land*

**MVRU**  
Mahidol Vivax Research Unit



- Chula Vaccine Research Center (Chula VRC)
- National Primate Research Center of Thailand

